Neurofibromin-deficient Schwann cells have increased lysophosphatidic acid dependent survival and migration - Implications for increased neurofibroma formation during pregnancy

GLIA

Volumn 55, Issue 5, 2007, Pages 527-536

  Nebesio, Todd D ^a   Ming, Wenyu ^a   Chen, Shi ^a   Clegg, Travis ^a   Yuan, Jin ^a   Yang, Yanzhu ^a   Estwick, Selina A ^a   Li, Yan ^a   Li, Xiaohong ^a   Hingtgen, Cynthia M ^a   Yang, Feng Chun ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

lpa; nf1; pi3 k; ras

Indexed keywords

F ACTIN; LYSOPHOSPHATIDIC ACID; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; SMALL INTERFERING RNA;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL MOTILITY; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; GENE MUTATION; MOUSE; NEUROFIBROMA; NONHUMAN; POLYMERIZATION; PREGNANCY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCHWANN CELL; SEQUENCE HOMOLOGY; WILD TYPE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ACTINS; ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; GANGLIA, SPINAL; LYSOPHOSPHOLIPIDS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROFIBROMA; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; PREGNANCY; PREGNANCY COMPLICATIONS; PROTO-ONCOGENE PROTEINS C-AKT; RAS GTPASE-ACTIVATING PROTEINS; SCHWANN CELLS; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC;

EID: 33847711059     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20482     Document Type: Article

References (57)

1. Barber SC, Mellor H, Gampel A, Scolding NJ. 2004. S1P and LPA trigger SC actin changes and migration. Eur J Neurosci 19:3142-3150.
2. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. 1992. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356:713-715.
3. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K. 1996. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12:144-148.
4. Cichowski K, Jacks T. 2001. Nf1 tumor suppressor gene function: Narrowing the gap. Cell 104:593-604.
5. Dasgupta B, Li W, Perry A, Gutmann DH. 2005. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res 65:236-245.
6. Datta SR, Brunet A, Greenberg ME. 1999. Cellular survival: A play in three akts. Genes Dev 13:2905-2927.
7. Donovan S, See W, Bonifas J, Stokoe D, Shannon KM. 2002. Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. Cancer Cell 2:507-514.
8. Dugoff L, Sujansky E. 1996. Neurofibromatosis type 1 and pregnancy. Am J Med Genet 66:7-10.
9. Ferner RE, O'Doherty MJ. 2002. Neurofibroma and schwannoma. Curr Opin Neurol 15:679-684.
10. Friedman JM. 1999. Epidemiology of neurofibromatosis type 1. Am J Med Genet 89:1-6.
11. Friedman JM, Birch PH. 1997. Type 1 neurofibromatosis: A descriptive analysis of the disorder in 1, 728 patients. Am J Med Genet 70:138-143.
12. Fukushima N, Ishii I, Contos JJ, Weiner JA, Chun J. 2001. Lysophospholipid receptors. Annu Rev Pharmacol Toxicol 41:507-534.
13. Guha A, Lau N, Huvar I, Gutmann D, Provias J, Pawson T, Boss G. 1996. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene 12:507-513.
14. Gutmann DH, Collins FS. 1993. The neurofibromatosis type 1 gene and its protein product, neurofibromin. Neuron 10:335-343.
15. Heinly CS, Sempowski GD, Lee DM, Patel DD, McDermott PM, Scearce RM, Thompson CB, Haynes BF. 2001. Comparison of thymocyte development and cytokine production in CD7-deficient, CD28-deficient and CD7/CD28 double-deficient mice. Int Immunol 13:157-166.
16. Hiatt KK, Ingram DA, Zhang Y, Bollag G, Clapp DW. 2001. Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-/- cells. J Biol Chem 276:7240-7245.
17. Huang Y, Rangwala F, Fulkerson PC, Ling B, Reed E, Cox AD, Kamholz J, Ratner N. 2004. Role of TC21/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells. Oncogene 23:368-378.
18. Huson SM, Harper PS, Compston DA. 1988. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east wales. Brain 111(Part 6):1355-1381.
19. Ingram DA, Hiatt K, King AJ, Fisher L, Shivakumar R, Derstine C, Wenning MJ, Diaz B, Travers JB, Hood A, Marshall M, Williams DA, Clapp DW. 2001. Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, co-operate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J Exp Med 194:57-69.
20. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. 1994. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 7:353-361.
21. Jalink K, Eichholtz T, Postma FR, van Corven EJ, Moolenaar WH. 1993. Lysophosphatidic acid induces neuronal shape changes via a novel, receptor-mediated signaling pathway: Similarity to thrombin action. Cell Growth Differ 4:247-255.
22. Kim HA, Ling B, Ratner N. 1997. Nf1-dencient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: Reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol Cell Biol 17:862-872.
23. Kim HA, Ratner N, Roberts TM, Stiles CD. 2001. Schwann cell proliferative responses to cAMP and Nf1 are mediated by cyclin dl. J Neurosci 21:1110-1116.
24. Kim HA, Rosenbaum T, Marchionni MA, Ratner N, DeClue JE. 1995. Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes. Oncogene 11:325-335.
25. Klose A, Ahmadian M, Schuelke M, Scheffzek K, Hoffmeyer S, Gewies A, Schmitz F, Kaufmann D, Peters H, Wittinghofer A, Nurnberg P. 1998. Selective disactivation of neurofibromin gap activity in neurofibromatosis type 1. Hum Mol Genet 7:1261-1268.
26. Kluwe L, Friedrich R, Mautner VF. 1999. Loss of NF1 allele in schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma. Genes Chromosomes Cancer 24:283-285.
27. Kobayashi T, Yamano S, Murayama S, Ishikawa H, Tokumura A, Aono T. 1994. Effect of lysophosphatidic acid on the preimplantation development of mouse embryos. FEBS Lett 351:38-40.
28. Kunikata K, Yamano S, Tokumura A, Aono T. 1999. Effect of lysophosphatidic acid on the ovum transport in mouse oviducts. Life Sci 65:833-840.
29. Lee J, Jung ID, Chang WK, Park CG, Cho DY, Shin EY, Seo DW, Kim YK, Lee HW, Han JW, Lee HY. 2005. P85 β-PIX is required for cell motility through phosphorylations of focal adhesion kinase and p38 MAP kinase. Exp Cell Res 307:315-328.
30. Lee JC, Kassis S, Kumar S, Badger A, Adams JL. 1999. P38 mitogen-activated protein kinase inhibitors - Mechanisms and therapeutic potentials. Pharmacol Ther 82:389-397.
31. Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, Bast RC Jr, Mills GB, Fang X. 2006. Lysophosphatidic acid is a major regulator of growth-regulated oncogene α in ovarian cancer. Cancer Res 66:2740-2748.
32. Li Y, Gonzalez MI, Meinkoth JL, Field J, Kazanietz MG, Tennekoon GI. 2003. Lysophosphatidic acid promotes survival and differentiation of rat Schwann cells. J Biol Chem 278:9585-9591.
33. Li Y, O'Connell P, Breidenbach HH, Cawthon R, Stevens J, Xu G, Neil S, Robertson M, White R, Viskochil D. 1995. Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics 25:9-18.
34. McCormick F. 1995. Ras signaling and nf1. Curr Opin Genet Dev 5:51-55.
35. Miller SJ, Li H, Rizvi TA, Huang Y, Johansson G, Bowersock J, Sidani A, Vitullo J, Vogel K, Parysek LM, DeClue JE, Ratner N. 2003. Brain lipid binding protein in axon-Schwann cell interactions and peripheral nerve tumorigenesis. Mol Cell Biol 23:2213-2224.
36. Mills GB, Moolenaar WH. 2003. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3:582-591.
37. Moolenaar WH. 2000. Development of our current understanding of bioactive lysophospholipids. Ann N Y Acad Sci 905:1-10.
38. Moolenaar WH, Kranenburg O, Postma FR, Zondag GC. 1997. Lysophosphatidic acid: G-protein signalling and cellular responses. Curr Opin Cell Biol 9:168-173.
39. Moolenaar WH, van Meeteren LA, Giepmans BN. 2004. The ins and outs of lysophosphatidic acid signaling. Bioessays 26:870-881.
40. Muir D, Neubauer D, Lim IT, Yachnis AT, Wallace MR. 2001. Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. Am J Pathol 158:501-513.
41. Radeff-Huang J, Seasholtz TM, Matteo RG, Brown JH. 2004. G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J Cell Biochem 92:949-966.
42. Riccardi VM. 1981. Von Recklinghausen neurofibromatosis. N Engl J Med 305:1617-1627.
43. Sivaprasad U, Fleming J, Verma PS, Hogan KA, Desury G, Cohick WS. 2004. Stimulation of insulin-like growth factor (IGF) binding protein-3 synthesis by IGF-I and transforming growth factor-α is mediated by both phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways in mammary epithelial cells. Endocrinology 145:4213-4221.
44. Stahle M, Veit C, Bachfischer U, Schierling K, Skripczynski B, Hall A, Gierschik P, Giehl K. 2003. Mechanisms in LPA-induced tumor cell migration: Critical role of phosphorylated ERK. J Cell Sci 116:3835-3846.
45. Swapp GH, Main RA. 1973. Neurofibromatosis in pregnancy. Br J Dermatol 88:431-435.
46. Tokumura A, Kanaya Y, Miyake M, Yamano S, Irahara M, Fukuzawa K. 2002a. Increased production of bioactive lysophosphatidic acid by serum lysophospholipase d in human pregnancy. Biol Reprod 67:1386-1392.
47. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, Fukuzawa K. 2002b. Identification of human plasma lysophospholipased, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 277:39436-39442.
48. Vlahos CJ, Matter WF, Hui KY, Brown RF. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269:5241-5248.
49. Weiner JA, Chun J. 1999. Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid. Proc Natl Acad Sci USA 96:5233-5238.
50. Weiner JA, Fukushima N, Contos JJ, Scherer SS, Chun J. 2001. Regulation of schwann cell morphology and adhesion by receptor-mediated lysophosphatidic acid signaling. J Neurosci 21:7069-7078.
51. Woods SA, Marmor E, Feldkamp M, Lau N, Apicelli AJ, Boss G, Gutmann DH, Guha A. 2002. Aberrant G protein signaling in nervous system tumors. J Neurosurg 97:627-642.
52. Yang PC, Atkinson SJ, Gu Y, Borneo JB, Roberts AW, Zheng Y, Pennington J, Williams DA. 2001. Rac and Cdc42 GTPases control hematopoietic stem cell shape, adhesion, migration, and mobilization. Proc Natl Acad Sci USA 98:5614-5618.
53. Yang PC, Ingram DA, Chen S, Hingtgen CM, Ratner N, Monk KR, Clegg T, White H, Mead L, Wenning MJ, Williams DA, Kapur R, Atkinson SJ, Clapp DW. 2003. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells. J Clin Invest 112:1851-1861.
54. Yang FC, Kapur R, King AJ, Tao W, Kim C, Borneo J, Breese R, Marshall M, Dinauer MC, Williams DA. 2000. Rac2 stimulates Akt activation affecting BAD/Bcl-XL expression while mediating survival and actin function in primary mast cells. Immunity 12:557-568.
55. Ye X, Ishii I, Kingsbury MA, Chun J. 2002. Lysophosphatidic acid as a novel cell survival/apoptotic factor. Biochim Biophys Acta 1585:108-113.
56. Zhang YY, Vik TA, Ryder JW, Srour EF, Jacks T, Shannon K, Clapp DW. 1998. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med 187:1893-1902.
57. Zhu Y, Parada LF. 2002. The molecular and genetic basis of neurological tumours. Nat Rev Cancer 2:616-626.